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REGULAR ARTICLE
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Key Points
• ADAMTS13 activities
may serve as biomarkers
to guide caplacizumab
treatment modalities
and overall treatment
duration.
• von Willebrand factor
activities may be used for
therapeutic drug moni-
toring of caplacizumab.
Introduction of the nanobody caplacizumab was shown to be effective in the treatment of
acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official
recommendations include plasma exchange (PEX), immunosuppression, and the use of
caplacizumab for a minimum of 30 days after stopping daily PEX. This study was
a retrospective, observational analysis of the use of caplacizumab in 60 patients from 29
medical centers in Germany. Immunosuppressive treatment led to a rapid normalization of
ADAMTS13 activities (calculated median, 21 days). In 35 of 60 patients, ADAMTS13 activities
started to normalize before day 30 after PEX; in 11 of 60 patients, the treatment was extended
beyond day 30; and in 5 patients, it was extended even beyond day 58 due to persistent
autoimmune activity. In 34 of 60 instances, caplacizumab was stopped before day 30 with
a favorable outcome whenever ADAMTS13 activities were .10%. In contrast, 11 of 34
patients with ADAMTS13 activities ,10% at the time of stopping caplacizumab treatment
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developed a nonfavorable outcome (disease exacerbation or relapse). In some cases,
prolongation of the treatment interval to every other day was feasible and resulted in
a sustained reduction of von Willebrand factor activity. ADAMTS13 activity measurements
are central for a rapid diagnosis in the acute setting but also to tailor disease management.
An ADAMTS13 activity–guided approach seems safe for identifying the individual time point
when to stop caplacizumab to prevent overtreatment and undertreatment; this approach
will result in significant cost savings without jeopardizing the well-being of patients. In
addition, von Willebrand factor activity may serve as a biomarker for drug monitoring.
Introduction
The advent of the anti–von Willebrand factor (VWF) humanized
nanobody caplacizumab has broadened the therapeutic armamen-
tarium for treating acute episodes of acquired thrombotic thrombo-
cytopenic purpura (aTTP). However, real-world safety and efficacy
outside of expert centers, effect of cost on utilization, adherence in
nonclinical trials, and optimal duration of therapy are unknown.1 The
high costs (on average, US$270000 per course) might also limit its
use. A retrospective, observational analysis2 on the use of caplacizu-
mab during acute disease management in 60 patients from 29medical
centers in Germany from June 2018 to December 2019 confirmed the
drug’s therapeutic potential as described in 2 double-blind controlled
trials; this led to the rapid approval of the drug in Europe and the United
States.3,4 In the German cohort, treatment modalities were very
heterogeneous. Caplacizumab was used as front-line treatment
in 35 (58.3%) of 60 patients. In this real-world cohort, caplacizumab led
to a rapid normalization of the platelet count in all patients as reported in
the TITAN (phase 2) andHERCULES (phase 3) trials.3,4 This effect was
very robust and was observed in patients in whom caplacizumab was
used early in treatment as well as in cases of refractory disease. The
delayed use of caplacizumab in a significant proportion of patients
resulted in a higher need of plasma exchange (PEX) (11.8 days vs
5.8 days in HERCULES), prolonged hospitalization (21.6 days vs 9.9
days), and 1 death related to aTTP-associated complications. After the
start of caplacizumab, however, only a median of 4 additional PEXwere
necessary, again confirming the published results from the HERCU-
LES trial. Moreover, recent reports have described PEX-free treatment
regimens of acute episodes of aTTP with caplacizumab with an overall
favorable outcome.5,6 With this growing body of evidence, caplacizu-
mab has become more and more widely accepted and is recom-
mended as front-line treatment for acute episodes of aTTP.
Official recommendations for the use of caplacizumab follow the
therapeutic scheme from the HERCULES trial.4 In addition to an
initial intravenous dose before PEX, daily subcutaneous injections
following PEX are recommended for an additional 30 days after PEX
is stopped. The guidelines also recommend extending the treatment
duration if ADAMTS13 activity remains ,10% thereafter. These
recommendations remain a matter of an ongoing scientific debate as
no pathophysiological or clinical justification has been reported for
a fixed treatment period.30 days after stopping PEX. On the contrary,
a prolongation in cases of persistent autoimmune activity seems
justified, although the exact length of the treatment extension must be
better defined.3 In HERCULES, patients experienced a disease relapse
after stopping caplacizumab 58 days after the last PEX, most likely due
to persistent autoantibodies and reduced ADAMTS13 activities.4 With
the increasing availability of caplacizumab, reliable markers for
treatment success and identification of laboratory and/or clinical
landmarks to control treatment should be quickly established.
Given its central role in the pathogenesis of aTTP, ADAMTS13 activity
measurements have gainedmuch interest not only for a rapid diagnosis
in the acute setting but also to tailor disease management.7-11 An
ADAMTS13-guided approach may enable physicians to identify the
individual time point when to stop caplacizumab to prevent
overtreatment and undertreatment. This action may also result in
significant cost savings without jeopardizing thewell-being of patients
with aTTP. The current article provides a comprehensive analysis
of the treatment modalities of the first 60 patients treated with
caplacizumab in Germany, infers strategies to reduce caplacizumab
doses by using VWF activity as a biomarker for drug monitoring, and
offers an analysis of cost-saving potential.
Methods
Study design and participants
This study was conducted as a retrospective, observational analysis
at 29 German medical centers. In total, 60 patients with aTTP were
identified who received caplacizumab between June 2018 and
December 2019. Time to final recovery of ADAMTS13 activity was
defined as the time to the first day with a measurement $10% that
was not followed by another measurement below this value unless this
was deemed due to a late relapse unrelated to the previous episode.
ADAMTS13 activity measurements with ongoing PEX were excluded.
Time to normalization of platelet count after caplacizumab treatment
start was defined as the first day with a count $150 3 10E9/L.
If caplacizumab treatment was stopped and resumed later due to
exacerbation or relapse, time to normalization was measured again
(as in cases #3, #28, #33, #38, #42, #43, and #57). Clinical
remission, exacerbation, refractory disease, and relapse were
defined as published previously, with the exception that re-
initiation of PEX was not a prerequisite of exacerbation and relapse
because some of these instances were managed with conservative
treatment only.12 Treatment according to the HERCULES protocol
was defined as caplacizumab initiated before or after the first PEX
and continued for a minimum of 30 days and a maximum of 58 days
after the last PEX treatment. Treatment decisions were interpreted
according to the reported laboratory parameters and therapeutic
interventions. In case of uncertainties regarding the rationale,
treating physicians were contacted in person, by telephone, or
by e-mail to clarify their decision-making process.
3094 VO¨LKER et al 14 JULY 2020 x VOLUME 4, NUMBER 13
VWF activity measurements
VWF activity measurements were performed at the respective
centers. The INNOVANCE-VWF-AC reagent (Siemens Healthcare
Diagnostics, Erlangen, Germany) on the Sysmex CS-5100, Atellica
COAG 360 platform, was used in all instances.
Analysis of cost-saving potential
The global cost-saving analysis comprises 3 independent calcu-
lations. First, we calculated the number of doses that were saved by
stopping caplacizumab treatment successfully, guided according to
either platelet count or ADAMTS13 activity, before completing 30
doses after PEX (following the HERCULES study protocol).
Instances in which this procedure resulted in an exacerbation or
relapse were not considered, and additional potential costs arising
from intensified treatment after unsuccessful attempts to stop
caplacizumab were not calculated. Second, the number of doses
saved by successfully switching patients to a nondaily administration
regimen was calculated. The total number of days on caplacizumab
after PEX was compared vs the actual number of doses administered
to the patient every other day. Third, we calculated the predicted
number of doses that could have been saved if caplacizumab
treatment had been stopped on the day of the first ADAMTS13
activity measurement .10% after PEX (ie, the consistent use of
ADAMTS13 activities to guide caplacizumab therapy duration). To
calculate total cost savings, hypothetical saved doses were multiplied
by €5660 or US$7660 as the marketing prices in Germany and the
United States, respectively, as of October 2019.
The individual caplacizumab dose and cost calculation involved
3 main strategies. First, the calculation of hypothetical doses if
a particular treatment had either been guided by: (1) the official
registration information of caplacizumab in the United States (ie, the
HERCULES protocol), (2) an ADAMTS13 activity–guided ap-
proach, and (3) an ADAMTS13 activity–guided approach with
alternate-day dosing after the end of PEX treatment. Second, a cost
calculation of each individual patient was provided based on the actual
treatment modalities (“real-world data”). Based on this real-world
evidence gathered herein, we report the actual doses per patient
and calculate saved caplacizumab doses for those patients who: (1)
have not completed 30 days of caplacizumab post-PEX based on
ADAMTS13 activity, (2) have not completed 30 days of caplacizumab
post-PEX based on platelet counts, or (3) have been switched to
a nondaily dosing regimen post-PEX. If stopping caplacizumab before
day 30 post-PEX led to an exacerbation or relapse, the estimated
costs of additional rituximab, ICU days, and PEX are also reported. Third,
we report the real-world data of total costs of conventional treatment
(rituximab, ICU days, and PEX). More details regarding the calculation
are given in the legend of Table 3 and supplemental Table 2.13,14
Statistical analysis
Given the exploratory nature of the current study, no sample size
calculation and no adjustments for multiple testing were performed.
All results are given as median (interquartile range) or mean with
95% confidence interval (CI) when appropriate. For the linear re-
gression analysis, the Mann-Whitney U test was used to determine
statistical significance. Statistical analysis was conducted by using
GraphPad Prism version 8.0.1 (GraphPad Software, San Diego,
CA). Figures and tables were designed and composed by using
Microsoft Office (Microsoft Corp, Redmond, WA) and Adobe
Illustrator (Adobe Systems Software Ireland Ltd, Dublin, Ireland).
Results
Individual patient characteristics, treatment modalities, and in-
dividual courses comprising platelet counts and ADAMTS13
activity measurements and therapeutic interventions are reported
in supplemental Table 1 and supplemental Figure 1 and are described
in detail by Voelker et al.2
ADAMTS13 activity as a biomarker to guide
treatment modalities
ADAMTS13 activities were regularly assessed during caplacizumab
treatment in 45 (75.0%) of 60 patients. The median time after
diagnosis to final ADAMTS13 activity recovery to .10% was 32.5
(8-204) days and 21 (1-191) days after stopping PEX treatment
(Figure 1). Thirty-five (58.3%) of 60 patients reached ADAMTS13
activities .10% before day 30 after stopping PEX (median,
21 days; range, 1-191 days). In a linear regression analysis, patients
with a first episode of aTTP took significantly less time to resolve
autoimmune activity and restore ADAMTS13 activity compared with
patients with recurrent disease. No other parameter was identified
to significantly correlate with time to ADAMTS13 activity recovery;
in particular, sex and body mass index had no effect (Table 1).
Caplacizumab was stopped before day 30 in 35 instances in 31 of
60 patients (Table 2). Of note, in 4 cases (cases #3, #24, #28, and
#38), caplacizumab was stopped twice before completion of a full
course of 30 doses. Case #18 was excluded from this analysis due
to the fatal outcome. In 20 of these instances, a platelet count–
guided approach (ie, thrombocytes .150 3 10E9/L) was used to
halt caplacizumab treatment. In 45% (9 of 20) of such instances,
the patients experienced a disease exacerbation. In 15 additional
instances, treatment was terminated before day 30 based on
restored ADAMTS13 activities. None of these patients developed
signs of exacerbation or early relapse during the follow-up period. In
11 of the reported 60 patients, treatment was extended beyond day
30 due to low ADAMTS13 activities. In one of these patients (#33),
caplacizumab was extended beyond day 30 in 2 instances. In a total
of 12 instances in these 11 patients, treatment was extended by an
average of 80.6 days (95% CI 55.9-105.3) post-PEX. No patient
with ADAMTS13 activity .10% at the time of stopping caplacizu-
mab treatment experienced an exacerbation or relapse within the
observation period. In contrast, 11 of 34 patients with ADAMTS13
activities ,10% at the time of stopping caplacizumab treatment
developed a nonfavorable outcome (ie, disease exacerbation or
relapse) (Figure 2). Of note, 10 of 11 events occurred within the first
4 weeks after stopping PEX, and all events occurred within 15 days
after stopping caplacizumab (mean, 6.9 days; 95% CI, 3.9-9.9).
Supplemental Table 1 lists the modifications of the immunosup-
pressant regimen that have been introduced after 30 days of
protracted autoimmune activity in the 15 patients in the upper
quartile with the longest time to ADAMTS13 activity normalization
after PEX (equal to $54 days after PEX). Additional immunosup-
pressive medications were introduced in 7 (46.7%) of 15 patients
and comprised mycophenolate, azathioprine, increased doses of
rituximab, and cyclosporine.
There is evidence that front-line rituximab treatment within 72 hours
after disease onset is superior to later treatment, with faster
attainment of remission and normalization of ADAMTS13 activity.15
In this cohort, 48 (80.0%) of 60 patients were treated with 1 to 6
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doses of rituximab, with a median cumulative dose of 2000mg (562.5-
5000 mg). On average, patients received the first dose of rituximab
on day 7 (0-26 days). In 11 (18.3%) of 60 patients, rituximabwas used
as a front-line agent. Surprisingly, the use of rituximab either as front-
line therapy within 72 hours after starting the specific treatment or later
had no impact on ADAMTS13 normalization (log-rank test, not
significant; x2 test, 2.563 [P 5 .278]; log-rank test for trend, not
significant; x2 test, 1.150 [P5 .284]). We also analyzed the impact of
the inhibitory autoantibody and antigen levels, remaining ADAMTS13
activity, and organ damage markers at presentation (lactate
dehydrogenase, troponin, creatinine, and Glasgow Coma Scale)
on ADAMTS13 recovery but observed no significant correlations.
VWF activity–based therapeutic drug monitoring
of caplacizumab
Based on the published pharmacokinetic parameters of caplacizu-
mab, 10 patients (cases #24, #29, #33, #34, #36, #37, #43, #44,
#47, and #50) were given a nondaily caplacizumab regimen
ranging from alternate-day to once weekly schedules and were
closely monitored for signs of disease activity.3 In 6 of these 10
cases, repeated measurements of VWF activity were conducted,
which revealed therapeutic inhibition over 48 hours (Figure 3). In
patients #29, #33, and #43, the dosing intervals were extended to
an alternate-day dosing regimen immediately after cessation of
PEX. In patient #34, VWF activity levels were.10% on days 1 and
2 after PEX, and the dosing interval was first extended on day 3 after
PEX when VWF activity was no longer detectable. Patients #36
and #37 were started on a daily caplacizumab regimen and
switched to alternate dosing intervals after 2 or 6 days, respectively.
In the 4 patients without repeated VWF activities (#24, #44, #47,
and #50), the treatment regimen in one (#24) did not follow
a particular dosing schedule but seemed to be primarily guided by
the day-to-day dynamic of the platelet count. However, no
deliberate attempt to elongate the dosing interval was made. In
the other instances (#44, #47, and #50), the patients were
switched to an alternate-day dosing regimen when ADAMTS13
became detectable (#44) or 1 week after the ADAMTS13 activity
had recovered and platelet counts had stabilized. The caplacizumab
treatment was stopped after an additional 19, 15, or 7 days (#44,
#47, and #50). On a cautionary note, however, 3 instances of
a drop in platelet count on an alternate-day caplacizumab dosing
regimen in 2 patients were observed. These instances were
asymptomatic, did not entail a rise in organ damage markers, and
could be managed by reverting to daily caplacizumab dosing for
a short period of time. In one patient (#58), 2 consecutive
caplacizumab doses in the early phase of the treatment were
accidentally omitted when platelet counts were already increasing.
This patient developed a prolonged phase of severe refractoriness.
Cost-saving potential
This study used a multimodal cost analysis, as indicated in the
Methods section and the legend to supplemental Table 2.13,14 A
global analysis summarizes the cost-saving potential of different
approaches to caplacizumab treatment guidance for all 60 patients
(ie, ADAMTS13 activity-guided, platelet count-guided, and nondaily
dosing regimens) (Table 3). The number of saved doses by
ADAMTS13 activity guidance or platelet count guidance was
calculated for those patients/instances in which caplacizumab was
successfully stopped before day 30. Caplacizumab was stopped
before day 30 in 35 instances (n 5 31 patients [4 patients had 2
instances]). This resulted in an estimated saving of 440 doses of
caplacizumab, approximating €2490 400/US$3388000.
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Figure 1. Kaplan-Meier curves of patient fractions remaining without ADAMTS13 activity (>10%) recovery after the end of PEX treatment.
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Nondaily dosing after PEX was used in 10 patients. The number of
saved doses was calculated by subtracting the actual doses from the
number of daily doses that patient would have received on a daily
dosing regimen. In 10 patients, nondaily dosing of caplacizumab saved
;386 daily doses (€2184760/US$2972200).
We next determined how many doses would have been saved if
caplacizumab had been stopped in all patients with an ADAMTS13
activity .10% before day 30 after PEX. In 29 of 60 patients,
caplacizumab treatment was continued despite ADAMTS13
activities .10%. In this hypothetical calculation, the early termina-
tion of caplacizumab treatment would have saved 419 doses
(€2371540/US$3226300).
Additional calculations of cost-saving strategies per patient are
given in supplemental Table 2.13,14 Here, we calculated the actual
cost of caplacizumab treatment (“as treated”) and the conventional
treatment modalities (rituximab, ICU days, and PEX). In cases of an
unsuccessful use of a cost-saving strategy, the cost to treat the
resulting exacerbation/relapse was also estimated (as outlined in
the figure legend). Due to the strong hypothetical nature of these
calculations, we abstained from summarizing results but rather
report individual data to elucidate cost effects of treatment
decisions in individual patients.
Discussion
With the increasing use of caplacizumab in the treatment of aTTP
comes the necessity to tailor treatment modalities to the individual
patient beyond well-standardized clinical trial settings. To prevent
Table 1. Outcomes data
Variable Germany (n 5 60) Statistical significance (Mann-Whitney U test)
Time to final ADAMTS13 activity recovery >10%
after diagnosis, median, d (IQR)
32.5 (21-53)
Reached at end of follow-up, % (n/N) 90.0 (54/60)
Not reached at end of follow-up, % (n/N) 10.0 (6/60)
Time to final ADAMTS13 activity recovery >10%
after end of PEX, median, d (IQR)
21 (9-48)
Reached at end of follow-up, % (n/N) 90.0 (54/60)
Not reached at end of follow-up, % (n/N) 10.0 (6/60)
Linear regression of time to final ADAMTS13
activity recovery >10% after end of PEX
Patients with first episode of aTTP (n 5 46)
P 5 .046 for difference between groups
Median, d (IQR) 18.0 (8.0-35.3)
Mean, d (SD) 29.3 (36.9)
Patients with recurrent aTTP, median (n 5 14)
Median, d (IQR) 45.5 (12.5-109.7)
Mean, d (SD) 61.4 (51.0)
Female patients (n 5 42)
P 5 .923 for difference between groups
Median, d (IQR) 21 (8.8-48.0)
Mean, d (SD) 35.2 (38.6)
Male patients (n 5 18)
Median, d (IQR) 21 (3.0-55.3)
Mean, d (SD) 40.6 (51.4)
Body mass index #24 kg/m2 (n 5 13)
P 5 .742 for difference between groups
Median, d (IQR) 23.0 (6.5-33.5)
Mean, d (SD) 23.1 (16.1)
Body mass index .24 kg/m2 (n 5 46)
Median, d (IQR) 18.0 (8.8-51.0)
Mean, d (SD) 38.9 (45.6)
N with available data as indicated.
IQR, interquartile range presented as quartile 1 and quartile 3 cutoff value; SD, standard deviation.
Table 2. Instances of early (<30 days post-PEX) termination of
caplacizumab treatment stratified according to outcome (ie,
nonsuccessful [exacerbation, relapse, or death] vs successful [no
such event])
Approach Successful Nonsuccessful
ADAMTS13 guided 15 0
Platelet count guided 11 9
Total 26 9
An ADAMTS13-guided approach was assumed when a (rising) ADAMTS13 activity
.10% was known to the treating physicians at the time of stopping caplacizumab. A
platelet count–guided approach was assumed when no such activity measurement was
known or activity was still ,10% at the time of stopping caplacizumab.
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undertreatment and overtreatment, as well as to alleviate the
socioeconomic burden, we performed a comprehensive analysis of
the first 60 patients treated with caplacizumab in Germany. The results
emphasize the importance of regular measurements of ADAMTS13
activities after PEX has been stopped and to discontinue caplacizumab
treatment once ADAMTS13 activity increases to .10%. In patients
with persistent autoimmune activity, a treatment extension for a total
of 58 days according to the HERCULES protocol seems justified
to overcome the initial period of maximal vulnerability. In addition,
VWF activity may prove useful as a biomarker for therapeutic drug
monitoring of caplacizumab, allowing extension of the treatment
interval and cost-savings without jeopardizing the patients’ well-being.
The pathophysiological hallmark of aTTP is the reduction of
ADAMTS13 activity mediated by autoantibodies against ADAMTS13.
Its measurement is of central importance in confirming the clinical
0
ADAMTS13 > 10%
ADAMTS13 < 10%
Duration of caplacizumab therapy after PEX [days]
20 40 60 150100 200
Favorable outcomeNon-favorable outcome (exacerbation/relapse/death)
Figure 2. Duration of caplacizumab treatment after end of PEX in relation to outcome. Caplacizumab treatment duration after PEX stratified according to
ADAMTS13 activity at the time of stopping caplacizumab. Nonfavorable outcomes include exacerbation, relapse, and death. Two cases were censored due to ongoing
caplacizumab treatment and registered as being in remission at the time point of the census. It is noteworthy that in 6 cases, .1 instance of termination of caplacizumab
treatment after PEX was reported. Days of caplacizumab treatment do not necessarily reflect the doses of caplacizumab because some patients were treated with a nondaily
or intermittent caplacizumab regimen.
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Figure 3. VWF activity as measured by a VWF:
GP1bM activity assay on the first and second day
after caplacizumab administration. Patients were on
an alternate-day caplacizumab treatment regimen and
closely monitored for signs of relapse. Normal range for
VWF activity, 50% to 187%. LL, lower limit of normal;
UL, upper limit of normal.
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diagnosis of aTTP. At the same time, ADAMTS13 autoantibodies
and activities can be used to identify patients at risk for disease
exacerbations and relapses in the weeks and months after an acute
episode. In the German cohort, the median time after diagnosis to
final ADAMTS13 activity recovery to .10% was 32.5 days and
21 days after stopping PEX treatment. This observation confirms
results from the HERCULES trial in which 26 of 65 (40%) patients
reported ADAMTS13 activities .10% in the week after the last
PEX and 17 of 60 (72%) patients at the end of the caplacizumab
treatment period. In HERCULES, no patient with ADAMTS13
activity .10% at the end of the treatment period experienced
a disease relapse, and only 3 of 30 in the placebo group
experienced an exacerbation if the ADAMTS13 activity was
.10% after the last PEX.4 We made similar observations in this
cohort. Recurrent aTTP was identified as a statistically significant
parameter that correlated with a prolonged time to normalization of
ADAMTS13 activities. These data suggest that ADAMTS13 activity
starts to normalize before day 30 and that it is highly unlikely that
exacerbation or relapse will occur with ADAMTS13 levels.10% on
adequate immunosuppression. As a consequence, ADAMTS13
activities should be monitored closely while administering caplaci-
zumab, and efforts should be made to improve its immediate
availability.
ADAMTS13 activity measurements are essential in the diagnosis of
aTTP, and monitoring seems to be promising for guiding treatment
decisions regarding duration and cotreatment. We therefore
advocate that ADAMTS13 activity measurements be available
within hours on a nationwide basis. It is of strong interest that new
tests become available that allow the rapid and fully automated
measurement of ADAMTS13 activity.16 We recommend monitoring
ADAMTS13 activity closely after termination of PEX and stopping
caplacizumab when activity rises .10%. Repeated measurements
at least 1 to 2 times per week resulted in a significant reduction of
the total administered dosage of caplacizumab. In addition, nondaily
administration of caplacizumab after PEX in patients with a low body
weight might help to further reduce total expenses; there is a small
risk of a disease exacerbation, however. Therefore, close monitoring
of the platelet count is necessary when choosing such an approach.
Direct measurements of VWF activity as a pharmacodynamic
marker may be beneficial to identify suitable candidates as well as
for therapeutic drug monitoring. Extending the treatment interval is
also an important option in patients who experience side effects but
are still depending on caplacizumab treatment for disease control. It
must be emphasized that all such modifications should be based on
broad agreement of clinicians and patients.
In many patients, we observed an excessive platelet count response
;10 days after the start of caplacizumab treatment, which was
followed by a drop of up to 30% to 40% between days 15 and
20 before reaching the individual normal levels. This dynamic
thrombocyte response was not accompanied by an increase in
lactate dehydrogenase or clinical signs of recurrent aTTP activity
(supplemental Figure 12). It most likely reflects increased thrombo-
poiesis in response to the underlying disease and the use of high-
dose glucocorticoids. As a consequence, it remains clinically
challenging to differentiate this observed drop in platelet count from
a potential disease exacerbation. Additional markers of hemolysis
(eg, lactate dehydrogenase, haptoglobin), as well as clinical symptoms,
might help to guide clinical decisions.
The autoimmune activity persisted in 11 patients, and caplacizumab
treatment was extended beyond day 30. In comparison, in
HERCULES, 20 of 73 patients were treated for.30 days. In detail,
2 patients had 1 week of treatment extension, 4 patients for 2
weeks, 5 patients for 3 weeks, and 9 patients for 4 weeks. The
HERCULES study was funded by Ablynx, Zwijnaarde, Belgium,
a Sanofi company. ClinicalTrials.gov identifier: NCT02553317;
internal study number: ALX0681-C301. The study started in 2015
and ended in 2017. Although caplacizumab treatment had to be
stopped in all patients after a maximum of 58 days in HERCULES,
the treatment was prolonged beyond 58 days in 6 instances (cases
#20, #24, #33, #34, and #36). Patient #33 experienced a relapse
after 65 days (ie, 7 days after stopping caplacizumab). The patient
was treated again for another 105 days until ADAMTS13 activities
began to normalize.
The first weeks after cessation of PEX remain critical, particularly
in patients with persistent autoimmune activity, and they justify
a treatment extension. However, one might consider cessation of
caplacizumab treatment in these high-risk patients after day 58
under close surveillance. In 5 of 6 incidences (1 case [#20] had
insufficient data), treatment was extended due to persistent
autoimmune activity. In this extended treatment subgroup, 2
instances of relapsing disease were documented, which could be
detected early and could be managed by conservative treatment
with no need for additional PEX. Of note, all exacerbations and
relapses occurred within 2 weeks after stopping caplacizumab,
again reproducing the observations described in the HERCULES
Table 3. Cost-saving strategies
Dose reduction strategy No. of instances calculated No. of saved doses Cost savings, € Cost savings, US$
Real-world data: early successful termination (platelet count
guided/ADAMTS13 guided) of caplacizumab treatment
26/60 440 2 490400 3388000
Real-world data: nondaily treatment regimens* 10/60 386 2 184760 2972200
Hypothetical model: ADAMTS13 guidance of caplacizumab
treatment duration†
29/60 419 2 371540 3226300
Real-world data and hypothetical cost-saving analysis investigating different dose reduction strategies in the German cohort in the post-PEX treatment period. Real-world data were based
on the dose reduction strategies used by the treating physicians. The hypothetical model investigates the potential savings if this strategy had been applied to all patients in the cohort.
Please note that these strategies are off-label and must be based on shared decision-making with the patient. Cost calculations are estimations based on the market price (January 2020) of
€5660 per dose and US$7700 per dose. Dose reduction strategies overlap in parts and cannot be considered complementary.
*Nondaily regimens ranged from alternate-day to once a week and may not be suitable for every individual or situation. VWF measurements may help identify suitable patients.
†The hypothetical model assumes that no exacerbation/relapse occur after ADAMTS13-guided termination of caplacizumab treatment. Although this might be inferred from the cohort
presented herein (no exacerbation/relapse in 14 of 14 attempts to stop caplacizumab treatment when ADAMTS13 activity has risen .10%), no prospective randomized data to support this
idea are available.
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trial in which all 9 subjects in the caplacizumab group with maximum
treatment extension duration permitted per protocol exhibited
suppressed ADAMTS13 activity at the time treatment was stopped.
Four of these 9 individuals developed a relapse within 8 days after
receiving the last dose of caplacizumab (Sanofi, data on file, shared
by the company). Hence, it seems reasonable to stop caplacizumab
treatment after 58 days even in patients with persistently low
ADAMTS13 activities and high autoantibody titers under close
surveillance. In case of a disease relapse, we recommend restarting
caplacizumab and consideration of additional immunosuppression.
However, one may also extend caplacizumab treatment until
autoimmune activity has resolved. In this case, an intensification of
immunosuppression ought to be considered, but no randomized
data support any specific therapy or dosing regimen in this context.
Rituximab has been shown to improve the response rates in aTTP
and increase relapse-free survival, particularly in patients experi-
encing disease relapses. Two studies argue in favor of adding
rituximab early in the course of acute aTTP to reduce PEX and
hospitalization.17,18 One might speculate whether its front-line use
in the era of caplacizumab will help to overcome the autoimmune
activity and lead to a more rapid normalization of ADAMTS13
activities. In the current cohort, 20% of all patients received
rituximab within the first 72 hours and 60% later during the course
of disease. Due to the retrospective nature of the study and
a potential immortal time bias, we were unable to quantify the effect
of rituximab on the time of ADAMTS13 activity normalization.
Furthermore, any analysis might be biased by the fact that
physicians tended to withhold rituximab in cases of rapidly waning
thrombotic microangiopathy and potentially milder courses or
administer it primarily to patients with refractory disease or
exacerbation. The fact that we were unable to identify predictive
factors of ADAMTS13 activity recovery except the presence
of a first episode of aTTP argues for front-line use of rituximab or
other immunosuppressant agents in all patients; this is important
because which patients will exhibit protracted autoimmune activity
remains unpredictable at the time of disease onset. Why autoimmune
activity in patients with recurrent aTTP requires longer to resolve
remains a question to be addressed, but one may speculate that
recurrent disease by itself defines more severe states of autoimmu-
nity. In the future, larger cohorts may help to identify other factors that
correlate with the time to resolution of autoimmunity.
As outlined previously, this retrospective observational study has
several limitations, including that it comprised very heterogeneous
treatment regimens. Another limitation was the fact that based on
the published aTTP disease incidence in Germany of 2.1 per
1 000000 per year, only;25% to 30% of cases treated for aTTP in
Germany during the observation period received caplacizumab.19,20
There seems to be a certain bias regarding disease severity and the
use of caplacizumab and rituximab.
In summary, the significance of ADAMTS13 activity measurements
has gained much interest. Its immediate availability poses a logistical
challenge but will lead to significant cost savings without jeopard-
izing the well-being of patients with aTTP. It seems reasonable to
tailor a caplacizumab treatment regimen based on ADAMTS13
activities. Based on these findings, we estimate that ;20% of
patients require caplacizumab beyond day 30, but that the majority
of patients can be treated with a shorter treatment course, resulting
in significant cost savings. In addition, VWF activity measurements
allow monitoring of caplacizumab pharmacodynamic parameters to
further reduce treatment costs and side effects during this life-
saving treatment.
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Supplement Figure 1 – Platelet counts and LDH-levels in relation to the start of caplacizumab 
treatment. Days -5 to 5 as published in Voelker et al. 
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Supplemental Table 1 – 15 cases with longest time (upper quartile) of low autoimmune activity 
(ADAMTS13 < 10 %): Comparison of initial immunosuppression and adaption of the 
immunosuppression in response to persistent autoimmune activity beyond day 30 post PEX.   
 
Case 
End of caplacizumab 
after disease/PEX 
onset (d) 
non-daily 
administration 
Time to ADAMTS13 
normalization after 
disease onset (d) 
Immunosuppression until day 
30 post PEX 
Immunosuppression after day 
30 post PEX 
#1 71/58 no 204 2000 mg RTX + GC no modification 
#33 188/179 (continued) 
yes 188 2000 mg RTX + GC MMF 
#24 222/177(continued) yes 185 2000 mg RTX (generic) + GC 
AZA; MMF; 3000 mg 
RTX (non-generic) 
#11 64/27 no 162 GC no modification 
#34 108/104 yes 123 2700 mg RTX + GC MMF 
#36 122/120 yes 122 1000 mg RTX + GC + CyA low dose 
1000 mg RTX + CyA 
high dose 
#17 4/0 no 113 562.5 mg RTX + GC no modification 
#14 4/0 no 112 1515 mg RTX + GC no modification 
#32 7/0 no 101 1000 mg RTX + GC no modification 
#41 56/31 no 93 2700 mg RTX + GC no modification 
#43 78/67 yes 76 2000 mg RTX + GC CyA 
#54 38/28 no 67 2100 mg RTX + GC 680 mg RTX 
#15 30/26 no 60 750 mg RTX + GC no modification 
#44 61/53 yes 55 2000 mg RTX + GC no modification 
#16 57/53 no 54 1000 mg RTX + GC AZA (not tolerated) CyA (not tolerated) 
 
Supplemental Table 2 - Necessary caplacizumab dose estimations using different models including 
cost calculation of adjunct conventional therapies.  
For cases #3, #24, #28 two instances were reported.  
* – censoring due to death (#18) or insufficient ADAMTS13 activity measurements on follow-up.  
(a) - Recommended number of daily doses of caplacizumab after PEX according to the official 
registration information in the US. Caplacizumab is to be continued for 30 days after PEX and may be 
extended by 7 days if signs of persistent autoimmune activity are present. This is limited to a 
maximum of 58 days (30 + 4 x 7 days) after PEX as per HERCULES protocol. European and FDA 
approvals differ in this regard.    
(b) - Recommended number of daily doses of caplacizumab if an ADAMTS13-guided approach was 
employed. This entails stopping caplacizumab once ADAMTS13 activity reaches values of 10% or 
above but not within 72h after stopping PEX (due to concerns of false positive activity measurements 
and unresolved autoimmune activity). Please note that delays in reporting the results of ADAMTS13 
activity measurements may lead to the administration of additional doses of caplacizumab, which 
could have been saved if test results became available faster.  
(c) - Recommended number of daily doses of caplacizumab after PEX if the decision to stop 
caplacizumab were based on an ADAMTS13-activity above or equal to 10% and caplacizumab were 
given every other day after the end of PEX. This model assumes sufficient suppression of vWF-
activity by alternate day administration of caplacizumab. We advise not to employ this dosing regimen 
uncritically due to safety concerns, particularly in patients with higher body weight and to monitor for 
disease activity closely. 
3 
 
(d) – Actual daily doses saved by employment of an ADAMTS13-guided approach to stopping 
caplacizumab, i.e. caplacizumab was stopped when ADAMTS13 activity rose to 10% or above. No 
cost calculations of inadvertent cost by subsequent exacerbations is given as no such instance was 
reported. 
(e) - Actual daily doses saved by employment of a platelet count-guided approach to stopping 
caplacizumab, i.e. caplacizumab was stopped when platelets rose to or above 150x10E9/l. This needs 
to be contrasted with inadvertent cost by exacerbation caused by early termination of caplacizumab 
(calculated in the adjacent column to the right). In case of an unsuccessful termination of 
caplacizumab treatment, potential cost savings are indicated in strike-through text.  
(f) - Costs of exacerbations were calculated when an unsuccessful attempt of stopping caplacizumab 
was made. Cost for additional PEX, rituximab doses, and ICU stays were calculated as indicated 
below (###). Additional caplacizumab doses, prolonged non-ICU hospital stays, and ancillary 
medications were not taken into consideration. 
(g) - Cost savings by non-daily caplacizumab dosing regimens were calculated subtracting the number 
of actual daily doses from the number of days of caplacizumab treatment (i.e. the number of daily 
doses if caplacizumab had been administered daily).  
(h) - Rituximab pricing (3,55 €/mg at 500 mg per vial) was determined by internal database research 
on April 22, 2020 at the University Hospital of Cologne, Germany using the cheapest available 
generic formula. Please note that this can be only an estimate and that prices may vary between 
institutions due to pricing policies in the German health care system. Pricing in other countries may 
differ significantly. Costs of an ICU stay per day (923 €/d) were based on published data by Moerer 
and colleagues from 2007.20 Costs per PEX (1098 €/PEX) were set at the current reimbursement rate 
as indicated in the Fallpauschalen-Katalog 2020 (as indicated under “Zusatzentgelt ZE36 – Anlage 
5”).21 
 
Saving 
potential
Treatment 
as is
ADAMTS13-
guided 
approach
Non-daily 
regimen RTX PEX ICU total
Case
official 
caplacizumab 
registrationa
ADAMTS13-
activity guidanceb
ADAMTS13-guided 
therapy + d2 regimenc
Difference official 
caplacizumab registration 
vs ADAMTS13-guidance
doses / costs doses / costs savedd doses / costs savede
additional costs 
(ICU, PEX, RTX) if 
relapsef
doses / costs savedg costs (€) costs (€) costs (€) costs (€)
1 # 58 191 96 -133 62 - - - - - - - - - - - -
€ 328280 1081060 543360 -752780 350920 7100 14274 2769 24143
2 # 58 48 24 10 61 - - - - - - - - - - - -
€ 328280 271680 135840 56600 345260 7100 6588 0 13688
3 # 30 26 13 4 7 - - - 4 - - - - - -
€ 169800 147160 73580 22640 39620 22640 7100 12078 11076 30254
# 27
€ 152820 11913
4 # 30 5 3 25 40 - - - - - - - - - - - -
€ 169800 28300 16980 141500 226400 8804 32940 13845 55589
5 # 30 3 2 27 37 - - - - - - - - - - - -
€ 169800 16980 11320 152820 209420 10828 16470 3692 30990
6 # 30 5 3 25 36 - - - - - - - - - - - -
€ 169800 28300 16980 141500 203760 0 8784 3692 12476
7 # 30 14 7 16 35 - - - - - - - - - - - -
€ 169800 79240 39620 90560 198100 0 5490 5538 11028
8 # 30 10 5 20 8 - - - 26 - - - - - -
€ 169800 56600 28300 113200 45280 147160 3550 7686 4615 15851
9 # 30 24 12 6 34 4 - - - - - - - - -
€ 169800 135840 67920 33960 192440 22640 7100 23058 0 30158
10 # 30 3 2 27 23 27 - - - - - - - - -
€ 169800 16980 11320 152820 130180 152820 7100 15372 0 22472
11* # 58 125 63 -67 48 - - - 3 - - - - - -
€ 328280 707500 356580 -379220 271680 16980 0 31842 2769 34611
12 # 30 15 8 15 34 1 - - - - - - - - -
€ 169800 84900 45280 84900 192440 5660 11076 7686 3692 22454
13 # 30 9 5 21 35 - - - - - - - - - - - -
€ 169800 50940 28300 118860 198100 0 7686 3692 11378
14 # 30 104 52 -74 4 - - - 30 - - - - - -
€ 169800 588640 294320 -418840 22640 169800 5378 8784 0 14162
15 # 37 36 18 1 30 4 - - - - - - - - -
€ 209420 203760 101880 5660 169800 22640 2663 28548 3692 34903
16 # 58 50 25 8 55 - - - - - - - - - - - -
€ 328280 283000 141500 45280 311300 3550 5490 0 9040
17 # 30 106 53 -76 5 - - - 30 - - - - - -
€ 169800 599960 299980 -430160 28300 169800 1997 7686 0 9683
18* # 0 0 0 0 2 - - - - - - - - - - - -
€ 0 0 0 0 11320 0 6588 4615 11203
19 # 30 11 6 19 30 18 - - - - - - - - -
€ 169800 62260 33960 107540 169800 101880 10650 16470 9230 36350
20 # 30 15 8 15 70 - - - - - - - - - - - -
€ 169800 84900 45280 84900 396200 0 3294 1846 5140
21 # 30 31 16 -1 50 - - - - - - - - - - - -
€ 169800 175460 90560 -5660 283000 0 13176 7384 20560
22 # 37 33 17 4 62 - - - - - - - - - - - -
€ 209420 186780 96220 22640 350920 2130 5490 3692 11312
23 # 30 12 6 18 39 - - - - - - - - - - - -
€ 169800 67920 33960 101880 220740 7100 20862 6461 34423
24 # 58 141 71 -83 82 - - - 30 111
€ 328280 798060 401860 -469780 464120 169800 9040 628260 17750 29646 0 47396
# 29
€ 164140 13938
25 # 30 29 15 1 38 - - - - - - - - - - - -
€ 169800 164140 84900 5660 215080 9585 39528 1846 50959
26 # 30 17 9 13 10 - - - 27 - - - - - -
€ 169800 96220 50940 73580 56600 152820 0 3550 12078 3692 19320
27 # 30 23 12 7 36 - - - - - - - - - - - -
€ 169800 130180 67920 39620 203760 3550 15372 1846 20768
28 # 30 3 2 27 16 23 - - - - - - - - -
€ 169800 16980 11320 152820 90560 130180 5403 12078 12922 30403
# 30
€ 169800 25088
29 # 30 24 12 6 18 - - - - - - - - - 14
€ 169800 135840 67920 33960 101880 79240 3550 9882 6461 19893
30 # 30 10 5 20 25 18 - - - - - - - - -
€ 169800 56600 28300 113200 141500 101880 2663 13176 2769 18608
31 # 30 10 5 20 33 - - - - - - - - - - - -
€ 169800 56600 28300 113200 186780 0 3294 1846 5140
32 # 58 92 46 -34 4 - - - 30 - - - - - -
€ 328280 520720 260360 -192440 22640 169800 3550 9882 4615 18047
33* # 58 184 92 -126 89 - - - - - - - - - 94
€ 328280 1041440 520720 -713160 503740 532040 8875 5490 5538 19903
34 # 58 119 60 -61 55 - - - - - - - - - 54
€ 328280 673540 339600 -345260 311300 305640 9585 5490 5538 20613
35 # 51 48 24 3 61 - - - - - - - - -
€ 288660 271680 135840 16980 345260 5811 3294 2769 11874
36 # 58 121 61 -63 62 - - - - - - - - - 59
€ 328280 684860 345260 -356580 350920 333940 7100 2196 n.d. n.d.
37 # 30 18 9 12 13 11 - - - - - - 5
€ 169800 101880 50940 67920 73580 62260 28300 7100 0 n.d. n.d.
38 # 30 2 1 28 28 19 27 - - -
€ 169800 11320 5660 158480 158480 107540 152820 21873 10068 14274 16614 40956
39 # 30 21 11 9 21 17
€ 169800 118860 62260 50940 118860 96220 8364 16470 n.d. n.d.
40 # 30 23 12 7 3 - - - 30 - - - - - -
€ 169800 130180 67920 39620 16980 169800 2663 5490 n.d. n.d.
41 # 58 68 34 -10 35 - - - - - - - - - - - -
€ 328280 384880 192440 -56600 198100 9585 45018 n.d. n.d.
42 # 37 42 21 -5 24 6 - - - - - - - - -
€ 209420 237720 118860 -28300 135840 33960 9368 8784 2769 20921
43 # 58 73 37 -15 40 - - - 21 29
€ 328280 413180 209420 -84900 226400 118860 3550 164140 7100 4392 3692 15184
44 # 51 49 25 2 52 - - - - - - - - - 10
€ 288660 277340 141500 11320 294320 56600 7100 8784 5538 21422
45 # 30 2 1 28 20 15 - - - - - - - - -
€ 169800 11320 5660 158480 113200 84900 2822 21960 3692 28474
46 # 30 18 9 12 39 - - - - - - - - - - - -
€ 169800 101880 50940 67920 220740 4381 4392 4615 13388
47 # 37 35 18 2 54 - - - - - - - - - 7
€ 209420 198100 101880 11320 305640 39620 7100 5490 2769 15359
48 # 30 1 1 29 37 - - - - - - - - - - - -
€ 169800 5660 5660 164140 209420 0 7686 5538 13224
49 # 30 3 2 27 30 - - - - - - - - - - - -
€ 169800 16980 11320 152820 169800 0 12078 13845 25923
50 # 30 21 11 9 20 5 - - - - - - 3
€ 169800 118860 62260 50940 113200 28300 16980 7100 3294 0 10394
51 # 30 8 4 22 17 - - - 15 - - - - - -
€ 169800 45280 22640 124520 96220 84900 9585 3294 2769 15648
52* # 30 34 17 -4 10 - - - 24 - - - - - -
€ 169800 192440 96220 -22640 56600 135840 0 4392 1846 6238
53 # 30 19 10 11 15 30 - - - - - - - - -
€ 169800 107540 56600 62260 84900 169800 10650 23058 18460 52168
54 # 58 57 29 1 32 - - - 2 - - -
€ 328280 322620 164140 5660 181120 11320 2414 12354 12078 11076 35508
55 # 30 8 4 22 39 - - - - - - - - - - - -
€ 169800 45280 22640 124520 220740 4828 9882 0 14710
56 # 30 8 4 22 8 - - - 22 - - - - - -
€ 169800 45280 22640 124520 45280 124520 0 0 0 0
57 # 30 6 3 24 45 10 - - - - - - - - -
€ 169800 33960 16980 135840 254700 56600 11133 31842 n.d. n.d.
58 # 30 2 1 28 30 18 - - - - - - - - -
€ 169800 11320 5660 158480 169800 101880 10650 21960 42458 75068
59* # 30 6 3 24 11 - - - 30 - - - - - -
€ 169800 33960 16980 135840 62260 169800 9040 7100 16470 5538 29108
60 # 30 27 14 3 20 - - - - - - - - - - - -
€ 169800 152820 79240 16980 113200 3550 5490 3692 12732
Daily caplacizumab dose requirement 
after  end of PEX and costs as 
determined by
Platelet guided approach
Conventional therapy costs (in €)h
Real-world data
Cost saving strategies (as employed)
Hypothetical models
Cost saving strategies (calculated)
